Pharmacotherapy: Quest for the quitting pill
C Willyard - Nature, 2015 - nature.com
C Willyard
Nature, 2015•nature.com… “What we're interested in is molecular mechanisms that may transcend a particular
addictive drug,” says Phil Skolnick, director of the division of pharmacotherapies and
medical consequences of drug abuse at the US National Institute on Drug Abuse (NIDA) in
Bethesda, Maryland. That is important, he says, because “many people who abuse drugs
don't abuse just one drug”. … In 2008, Zaveri founded a company called Astraea,
headquartered in Mountain View, California, to develop AT-1001 and similar compounds as …
addictive drug,” says Phil Skolnick, director of the division of pharmacotherapies and
medical consequences of drug abuse at the US National Institute on Drug Abuse (NIDA) in
Bethesda, Maryland. That is important, he says, because “many people who abuse drugs
don't abuse just one drug”. … In 2008, Zaveri founded a company called Astraea,
headquartered in Mountain View, California, to develop AT-1001 and similar compounds as …
Addiction researchers are optimistic that they can create effective medication to treat addictions. But the key question is, will pharmaceutical companies bring them to market?
nature.com
Bestes Ergebnis für diese Suche Alle Ergebnisse